Piflufolastat
Piflufolastat, also known as DCFPYL is a PSMA-targeted PET imaging agent for prostate cancer. Piflufolastat F-18 is a radioactive diagnostic agent used for positron emission tomography (PET) imaging. It was approved in 2021. Piflufolastat we are supplying is not radio-label compound.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Piflufolastat |
|---|---|
| Iupac 化学名称 | (((S)-1-carboxy-5-(6-fluoronicotinamido)pentyl)carbamoyl)-L-glutamic acid |
| 同义词 | DCFPYL; Piflufolastat; |
| 英文同义词 | DCFPYL; Piflufolastat; |
| 分子式 | C18H23FN4O8 |
| 分子量 | 442.40 |
| Smile | O=C(O)CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCCCNC(C1=CC=C(F)N=C1)=O)=O |
| InChiKey | OLWVRJUNLXQDSP-RYUDHWBXSA-N |
| InChi | InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1 |
| Cas号 | 1423758-00-2 |
| 相关CAS号 | 1423758-00-2 (F-19) |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | 类白色固体 |
|---|---|
| 纯度 | ≧96% |
| 存储 | 短期（几天到几周）为0-4摄氏度，长期（几个月）为-20摄氏度 |
| 可溶性 | 溶于DMSO |
| 处理方式 | Refer to MSDS |
| 运输条件 | 作为非危险化学品在环境温度下装运。这种产品在正常运输和海关工作期间可以稳定几周. |
| 海关编码 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Bouvet V, Wuest M, Bailey JJ, Bergman C, Janzen N, Valliant JF, Wuest F. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile. Mol Imaging Biol. 2017 Dec;19(6):923-932. doi: 10.1007/s11307-017-1102-x. PubMed PMID: 28639122.
2: Basuli F, Zhang X, Woodroofe CC, Jagoda EM, Choyke PL, Swenson RE. Fast indirect fluorine-18 labeling of protein/peptide using the useful 6-fluoronicotinic acid-2,3,5,6-tetrafluorophenyl prosthetic group: A method comparable to direct fluorination. J Labelled Comp Radiopharm. 2017 Mar;60(3):168-175. doi: 10.1002/jlcr.3487. Epub 2017 Feb 1. PubMed PMID: 27990672; PubMed Central PMCID: PMC5344719.
3: Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688. doi: 10.1007/s00259-016-3573-4. Epub 2016 Nov 26. PubMed PMID: 27889802; PubMed Central PMCID: PMC5323462.
4: Kelly J, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C Jr, Ponnala S, Babich JW. Synthesis and pre-clinical evaluation of a new class of high-affinity (18)F-labeled PSMA ligands for detection of prostate cancer by PET imaging. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):647-661. doi: 10.1007/s00259-016-3556-5. Epub 2016 Nov 15. PubMed PMID: 27847991; PubMed Central PMCID: PMC5323493.
5: Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol. 2015 Aug;17(4):575-84. doi: 10.1007/s11307-015-0866-0. PubMed PMID: 26013479; PubMed Central PMCID: PMC4493776.
